Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Return on Invested Capital (2023 - 2025)

Lyra Therapeutics has reported Return on Invested Capital over the past 3 years, most recently at 4.13% for Q4 2025.

  • Quarterly results put Return on Invested Capital at 4.13% for Q4 2025, up 1011.0% from a year ago — trailing twelve months through Dec 2025 was 4.13% (up 1011.0% YoY), and the annual figure for FY2025 was 70.77%, down 6886.0%.
  • Return on Invested Capital for Q4 2025 was 4.13% at Lyra Therapeutics, down from 25.9% in the prior quarter.
  • Over the last five years, Return on Invested Capital for LYRA hit a ceiling of 25.9% in Q3 2025 and a floor of 15.18% in Q2 2025.
  • Median Return on Invested Capital over the past 3 years was 1.95% (2024), compared with a mean of 1.03%.
  • Peak annual rise in Return on Invested Capital hit 2983bps in 2025, while the deepest fall reached -1323bps in 2025.
  • Lyra Therapeutics' Return on Invested Capital stood at 0.77% in 2023, then crashed by -673bps to 5.98% in 2024, then skyrocketed by 169bps to 4.13% in 2025.
  • The last three reported values for Return on Invested Capital were 4.13% (Q4 2025), 25.9% (Q3 2025), and 15.18% (Q2 2025) per Business Quant data.